Drug Trial Radar · NCT04832100
Bio-significance of LPC16:0 in Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
245
Planned (sponsor's estimate)
Start
Jun 1, 2021
Primary completion
Jun 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Kaohsiung Medical University Chung-Ho Memorial HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 5, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
Summary
As written by the sponsor on the registry.
Fibromyalgia (FM) is a very common but mysterious pain disorder characterized by chronic widespread muscular pain. Fatigue, anxiety and depression are common comorbidities. The syndrome is commonly associated with several symptoms, including fatigue, sleeping disturbance, cognitive impairment, and comorbid pain syndrome, especially irritable bowel symptoms and temporomandibular disease. Anxiety and depression are common psychiatric co-morbidies. Daily stress is believed to trigger or aggravate pain conditions. These symptoms can markedly affect patients' quality of life, and even lead to disability. So far, the etiology and pathogenesis are largely unknown, and diagnostic biomarkers and curative treatment remain to be developed. Recent technological advances enable scientists to explore mechanisms by genetic, transcriptomic, proteomic, and metabolomic researches. However, no definitive result has been concluded for clinical practice so far. In this study, the investigators use tailored questionnaires to evaluate fibromyalgia and associated symptoms, including numeric rating scale for soreness, widespread soreness index, Fibromyalgia impact questionnaire, Hospital Anxiety and Depression Scale, and perceived stress scale. The investigators also use metabolomics and lipidomic approach to probe the potential pathophysiology of fibromyalgia. In our prior translation research (PMID: 32907805), the investigators found that excessive LPC16:0 resulting from lipid oxidization inflicts psychological stress-induced chronic non-inflammatory pain via activating ASIC3. In this content, our prior translational research identified a potential nociceptive ligand that causes fibromyalgia symptoms, which is likely to function as biomarkers for diagnosis or disease monitor. In the current clinical investigation, the investigators aim to reversely translate the novel findings in animal studies and validate the bio-significance of LPC16:0 for fibromyalgia with clinical approaches.
Conditions
- Fibromyalgia, Primary
- Pain
- Soreness, Muscle
- Oxidative Stress
- Metabolomics
- Lipidomics
Interventions
Pregabalin 150mg, imipramine 25mgDrug
Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Questionnaire: Numeric rating scale (NRS) for pain and sorenessTime frame: Changes from baseline NRS at 2 weeks are assessed
- Questionnaire: Numeric rating scale (NRS) for pain and sorenessTime frame: Changes from baseline NRS at 4 weeks are assessed
- Questionnaire: widespread pain index and widespread soreness indexTime frame: Change from baseline widespread index at 2 weeks are assessed
- Questionnaire: widespread pain index and widespread soreness indexTime frame: Change from baseline widespread index at 4 weeks are assessed
- Questionnaire: Fibromyalgia impact questionnaire (FIQR)Time frame: Change from baseline FIQR at 2 weeks are assessed
- Questionnaire: Fibromyalgia impact questionnaire (FIQR)Time frame: Change from baseline FIQR at 4 weeks are assessed
- Questionnaire: Hospital Anxiety and Depression Scale (HADS)Time frame: Change from baseline HADS at 2 weeks are assessed
- Questionnaire: Hospital Anxiety and Depression Scale (HADS)Time frame: Change from baseline HADS at 4 weeks are assessed
- Questionnaire: The Pittsburgh Sleep Quality Index (PSQI)Time frame: Change from baseline PSQI at 2 weeks are assessed
- Questionnaire: The Pittsburgh Sleep Quality Index (PSQI)Time frame: Change from baseline PSQI at 4 weeks are assessed
- Questionnaire: Perceived stress scale (PSS)Time frame: Change from baseline PSS at 2 weeks are assessed
- Questionnaire: Perceived stress scale (PSS)Time frame: Change from baseline PSS at 4 weeks are assessed
- Metabolomics investigationTime frame: Change from baseline metabolomics at 3 months are assessed
- Lipidomics investigationTime frame: Change from baseline metabolomics at 3 months are assessed
- Metabolomics investigationTime frame: Change from baseline metabolomics at 6 months are assessed
- Lipidomics investigationTime frame: Change from baseline metabolomics at 6 months are assessed
- Metabolomics investigationTime frame: Change from baseline metabolomics at 9 months are assessed
- Lipidomics investigationTime frame: Change from baseline metabolomics at 9 months are assessed
- Metabolomics investigationTime frame: Change from baseline metabolomics at 12 months are assessed
- Lipidomics investigationTime frame: Change from baseline metabolomics at 12 months are assessed
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.